What a large GLP-1 meta-analysis reported about arrhythmia risk
A network meta-analysis in Heart Rhythm pooled 94 randomized trials and about 156,000 people to compare GLP-1 receptor agonists and co-agonists on new-onset arrhythmias, especially atrial fibrillation. Subcutaneous semaglutide ranked highest for lower AF incidence, but the authors call for more arrhythmia-focused studies to confirm the signal.
This is a study in people, not animals or cells. The researchers combined data from previously published randomized controlled trials, so no new patients were treated for this analysis. They pooled existing results to compare medications against each other and against placebo.
The paper, titled "Glucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias: A Network Meta-Analysis," appeared in Heart Rhythm. It focused on whether GLP-1 receptor agonists and co-agonists are linked to new-onset irregular heart rhythms, with particular attention to atrial fibrillation, often shortened to AF.
What the researchers studied
Arrhythmias frequently travel alongside conditions like diabetes and obesity, which can affect how they start and worsen. The authors wanted to know how different GLP-1 medications relate to the appearance of new arrhythmias in people who have diabetes or obesity.
They searched databases from inception through December 2025 and kept only randomized controlled trials. The final analysis included 94 trials and 155,989 patients, comparing 12 different GLP-1 receptor agonists and co-agonists. A network meta-analysis lets researchers rank treatments even when they were not all tested head-to-head in the same trial.
What they reported
Subcutaneous semaglutide ranked as the most effective intervention for reducing AF incidence. Compared with placebo, it was associated with a lower AF risk (risk ratio 0.82; 95% confidence interval 0.68 to 0.99). Compared with tirzepatide, it was also associated with lower AF risk (risk ratio 0.57; 95% confidence interval 0.37 to 0.88).
The ranking scores tell a similar story. On a scale where 1 is best and 0 is worst, semaglutide scored 0.7885 for AF, while tirzepatide scored 0.1830 and dulaglutide 0.1750. The authors reported that dulaglutide was linked to an increased AF risk, and that lixisenatide was associated with a decreased risk of atrioventricular blocks.
What this does and does not establish
This analysis describes statistical associations across many trials. It suggests subcutaneous semaglutide ranked highest for lower AF incidence in this pooled population. It does not prove that any GLP-1 medication prevents arrhythmias in a given person, and it does not mean these drugs are a treatment for AF.
The results apply to people studied in the original trials, who had diabetes or obesity. They do not tell you what will happen to any individual. Outcomes vary from person to person, and a heart rhythm concern is something to raise with a clinician who knows your history.
One honest limitation
The authors themselves state that further studies focusing on arrhythmic outcomes are needed to confirm these findings. Most GLP-1 trials were not designed primarily to measure arrhythmias, so these signals come from secondary data rather than studies built to answer this exact question. A network meta-analysis also relies on indirect comparisons, which carry more uncertainty than direct head-to-head trials.
How this connects to care
Two medications named in this study are ones Live Vital offers through physician-prescribed care: semaglutide and tirzepatide. Neither is positioned here as a heart rhythm treatment, and nothing in this abstract changes what either medication is approved or prescribed to do.
If you are considering physician-prescribed care, it begins with a medical intake and physician approval at /get-started, and you can book a free consult at /consult. A prescription is never guaranteed, and a physician determines what is appropriate after reviewing your health history. Live Vital does not accept insurance, though HSA and FSA funds are generally eligible.